Management of post-chemotherapy residual masses in advanced seminoma

被引:62
|
作者
Fléchon, A [1 ]
Bompas, E [1 ]
Biron, P [1 ]
Droz, JP [1 ]
机构
[1] Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon, France
来源
JOURNAL OF UROLOGY | 2002年 / 168卷 / 05期
关键词
testes; seminoma; drug therapy; cisplatin; neoplasm; residual;
D O I
10.1016/S0022-5347(05)64275-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We studied the resection of post-chemotherapy residual masses (20% to 80%) of advanced seminoma complicated by extensive fibrosis, in which active disease appears in 10% to 20% of cases. Materials and Methods: We retrospectively analyzed (1986 to 2000) residual mass evolution according to size in 79 platinum treated patients. Results: There was an evaluable response in 78 patients, including toxic death in 1 after 1 chemotherapy cycle, a complete response in 34 (after chemotherapy in 15 and after complete residual mass resection in 19), a marker negative partial response in 42 (incomplete residual mass resection in 8), stable and progressive disease in 1 each. In 15 of 31 patients the resected residual mass was 3 cm. or greater, whereas in 12 of 29 it was less than 3 cm. No surgery was performed for 3 residual masses of unknown size. Of the 42 residual masses 21 disappeared at a median of 12.5 months. Progression occurred at the initial tumor site in 11 of 13 patients after a median of 3.5 months, including 3 with a complete response, 8 with a marker negative partial response (residual mass 3 cm. or greater in 3, less than 3 cm. in 4 and unknown size in 1) and treatment failure in 2 (residual mass 3 cm. or greater). At a median followup of 36.4 months 67 patients survived (no disease progression in 56 and nonevolving residual masses in 11), while 12 had died including 9 of progressive disease 1 of toxicity and 2 of other causes. Conclusions: In our study there was incomplete surgical resection in 30% of cases. Relapse in 16.6% of cases occurred rapidly after the end of chemotherapy. Viable cells were only noted in residual masses 3 cm. or greater (13%) and 50% of residual masses disappeared during surveillance. We intend. to perform a prospective cohort study with close followup of patients with residual masses less than 3 cm. using an indication for surgery tailored to positron emission tomography findings in those with residual masses 3 cm. or greater.
引用
收藏
页码:1975 / 1979
页数:5
相关论文
共 50 条
  • [1] Surgery for a post-chemotherapy residual mass in seminoma
    Herr, HW
    Sheinfeld, J
    Puc, HS
    Heelan, R
    Bajorin, DF
    Mencel, P
    Bosl, GJ
    Motzer, RJ
    JOURNAL OF UROLOGY, 1997, 157 (03): : 860 - 862
  • [2] Management of post-chemotherapy extra-retroperitoneal residual masses
    Carver, Brett S.
    Sheinfeld, Joel
    WORLD JOURNAL OF UROLOGY, 2009, 27 (04) : 489 - 492
  • [3] Management of post-chemotherapy extra-retroperitoneal residual masses
    Brett S. Carver
    Joel Sheinfeld
    World Journal of Urology, 2009, 27 : 489 - 492
  • [4] Post-chemotherapy residual masses in testicular tumors
    Rodriguez Gomez, Ignacio
    Alvarez Castelo, Luis M.
    Gomez Veiga, Francisco A.
    Martinez Breijo, Sara
    Chantada Abal, Venancio
    Gonzalez Martin, Marcelino
    ACTAS UROLOGICAS ESPANOLAS, 2009, 33 (06): : 720 - 720
  • [5] Management of post-chemotherapy residual masses in testicular tumor and surgical tecnique
    Ates, Ferhat
    Yilmaz, Omer
    Baykal, Kadir Vehbi
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2011, 10 (03): : 68 - 74
  • [6] The management of residual masses after chemotherapy in metastatic seminoma
    Ravi, R
    Ong, J
    Oliver, RTD
    Badenoch, DF
    Fowler, CG
    Hendry, WF
    BJU INTERNATIONAL, 1999, 83 (06) : 649 - 653
  • [7] Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient?
    Rabbani, F
    Goldenberg, SL
    Gleave, ME
    Paterson, RF
    Murray, N
    Sullivan, LD
    BRITISH JOURNAL OF UROLOGY, 1998, 81 (02): : 295 - 300
  • [8] PET-CT for the management of testicular seminoma patients with post- chemotherapy residual masses
    Corsi, Oscar
    Rada, Gabriel
    Pena, Jose
    MEDWAVE, 2019, 19 (04):
  • [9] Postchemotherapy residual masses in advanced seminoma: current management and outcomes
    Quek, Marcus L.
    Simma-Chiang, Vannita
    Stein, John P.
    Pinski, Jacek
    Quinn, David I.
    Skinner, Donald G.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (05) : 869 - 874
  • [10] Management of residual masses after induction chemotherapy in advanced seminoma patients: Cancer Research Center experience
    Tjulandin, SA
    Bulanov, AA
    Titov, DA
    Zharkov, SA
    Sholokhov, VN
    Mikhina, ZP
    Lukianchenko, AB
    Garin, AM
    GERM CELL TUMOURS IV, 1998, : 143 - 148